IRON
Disc Medicine, Inc.NASDAQHealthcare$65.18+0.62%ClosedMarket Cap: $2.49B
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.11
P/S
0.00
EV/EBITDA
-11.58
DCF Value
$2.31
FCF Yield
-7.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-32.8%
ROA
-26.3%
ROIC
-30.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-60.5M | $-1.64 |
| FY 2025 | $0.00 | $-212.2M | $-6.01 |
| Q3 2025 | $0.00 | $-62.3M | $-1.77 |
| Q2 2025 | $0.00 | $-55.2M | $-1.58 |
Analyst Ratings
View AllWells FargoOverweight
2026-03-02Truist SecuritiesBuy
2026-02-27Cantor FitzgeraldOverweight
2026-02-17StifelBuy
2026-02-17WedbushOutperform
2026-02-17Trading Activity
Insider Trades
View AllSavage William Jacobofficer: Chief Medical Officer
SellWed Mar 04
Savage William Jacobofficer: Chief Medical Officer
SellWed Mar 04
Franchi Jean M.officer: Chief Financial Officer
SellFri Feb 27
Franchi Jean M.officer: Chief Financial Officer
SellThu Feb 19
Franchi Jean M.officer: Chief Financial Officer
SellThu Feb 19
Latest News
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.54
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.